Oxford Global, Novotel London West, One Shortlands, London, W6 8DR
3rd & 4th April 2014
Over 400 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions 25 presentations, case studies and panel discussions focused on the key issues in follow-on biologics development and commercialisation 2 interactive streams: - Market Opportunities and Commercial Challenges
- Developing Biosimilars and Biobetters
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities Co-located with the 7th Annual Proteins & Antibodies Congress & the Peptides Congress Oxford Global are proud to present the Biosimilars & Biobetters Congress, taking place on 3-4 April 2014 at Novotel London West, UK. The follow on biologics industry is forecast to reach $8.8 billion by 2017. Our conference programme focuses on the challenges, innovations and technologies that promise to put this sector at the forefront of the pharmaceutical industry. The 2nd Annual Biosimilars and Biobetters Congress features two streams: Market Opportunities & Commercial Challenges: In Stream 1, the meeting will address the most pressing challenges in gaining access to emerging markets and branding biosimilars through a series of cutting-edge conference presentations. Our boisimilars experts will also debate how to overcome regulatory challenges, outsource manufacturing and develop pricing strategies Developing Biosimilars & Biobetters: Learn more about current developments in clinical trials, including pharmacovigilence and patient safety. Do not miss out on the chance to discover innovative solutions for achieving quality by design, demonstrating biosimilarity and addressing potency as well as the latest insights into the regulatory requirements and trial design. The Biosimilars & Biobetters Congress is part of the highly successful Oxford Global Proteins Series.
|
|
|
Invited Speakers:
|
|
- Peter de Veene
EU Qualified Person for Pharmacovigilance, Roche - Sheka Ganese
Scientific Director, Genzyme - JiJie Gu
Principal Scientist, Abbott - Jason Li
Scientific Director, Genor Biopharma - Bernd Liedert
Director, Head of Immunopharmacology, Merck Serono - Mohamed Oubihi
Associate Director, Regulatory Affairs, Abbott - Angela Thomas
Chair of Biologicals and Vaccines Expert Advisory Group-Comission on Human Medicines, MHRA - Jaap Venema
Therapeutic Area Lead Biotherapeutics, AbbVie - Nils Wilking
Professor, Karolinska Insitute - Jianguo Yang
Principal Scientist, Senior Manager, Genzyme
|
|